On July 8, RemeGen rose 5.44% in regular trading, trading at HK$86.15/share, with turnover of HK$492 million.

On the news front, China's National Healthcare Security Administration recently published the preliminary review results for the basic medical insurance drug catalog and commercial insurance innovative drug catalog adjustment, with an overall pass rate of 92%, up 8 percentage points year-over-year. Key therapeutic areas including ADC, bispecific antibodies, and autoimmune diseases all saw major product submissions. RemeGen's core product Telitacicept has now secured approval for five indications, with expectations for medical insurance inclusion of its newly approved IgA nephropathy and Sjogren's syndrome indications continuing to build.

Additionally, lock-up shareholders whose 193 million shares (34.16% of total equity) became eligible for trading on July 1 are effectively restricted from reducing holdings via centralized bidding or block trades due to insufficient cash dividend distributions, significantly alleviating market concerns over selling pressure. Broader sector momentum also provided support, with innovative drug concept stocks rallying across the board in Hong Kong.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)